Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
The glucagon-like peptide receptor (GLP-1R), which is a G-protein coupled receptor (GPCR), signals through both Gαs and Gαq coupled pathways and ERK phosphorylation to stimulate insulin secretion. The aim of this study was to determine molecular details of the effect of small molecule agonists, compounds 2 and B, on GLP-1R mediated cAMP production, intracellular Ca2+ accumulation, ERK phosphorylation and its internalisation. In human GLP-1R (hGLP-1R) expressing cells, compounds 2 and B induced cAMP production but caused no intracellular Ca2+ accumulation, ERK phosphorylation or hGLP-1R internalisation. GLP-1 antagonists Ex(9-39) and JANT-4 and the orthosteric binding site mutation (V36A) in hGLP-1R failed to inhibit compounds 2 and B induced cAMP production, confirming that their binding site distinct from the GLP-1 binding site on GLP-1R. However, K334A mutation of hGLP-1R, which affects Gαs coupling, inhibited GLP-1 as well as compounds 2 and B induced cAMP production, indicating that GLP-1, compounds 2 and B binding induce similar conformational changes in the GLP-1R for Gαs coupling. Additionally, compound 2 or B binding to the hGLP-1R had significantly reduced GLP-1 induced intracellular Ca2+ accumulation, ERK phosphorylation and hGLP-1R internalisation. This study illustrates pharmacology of differential activation of GLP-1R by GLP-1 and compounds 2 and B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since the GLP-1 receptor (GLP-1R) agonists are effective in treating diabesity, they could be pharmacological alternatives to bariatric surgery but without the post-surgery complications.3,13,14”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The K334A mutation (which affects the Gαs coupling) of GLP-1R inhibited both GLP-1 and compounds 2 and B induced cAMP production, which demonstrates that GLP-1 and both compounds 2 and B induce similar conformational changes needed for the Gαs activation.14”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Compounds 2 and B induced cAMP production in human GLP-1R expressing cells but caused no intracellular Ca2+ accumulation, ERK phosphorylation or receptor internalisation.14”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [14]
In the citing paper
“Compounds A and B have also been shown to demonstrate ago-allosteric properties and induce cyclic adenosine monophosphate (cAMP) signalling, as well as increased insulin secretion in rat islets and animal studies.3,14”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [14]
In the citing paper
“Compounds 2 and B bind to a distinct site from the orthosteric binding site, as GLP-1R antagonists exendin (9–39) and JANT4, as well as the V36A mutation in GLP-1R, did not inhibit cAMP production upon compound 2 or B administration.14”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“The agonist occupied GLP-1R signals through both the Gαs and Gαq coupled pathways [3, 5, 6].”
BackgroundGöke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 5×
“Ex(9–39) and JANT-4 are known antagonist of the GLP-1R that work by binding to the orthosteric binding site [9, 10, 26, 32], which therefore competitively inhibit GLP-1 binding to the receptor.”
BackgroundInfluentialMechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Regulation of GPCRs by Endocytic Membrane Trafficking and Its Potential Implications
Hanyaloglu, A. C., & Zastrow, M. V. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094830 · Cited by 609 · cited 1×
“Reducing hGLP-1R internalisation prevents dampening of the receptor activity [43].”
BackgroundThorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558
Allosteric Modulation of the Cannabinoid CB1 Receptor
Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016162 · Cited by 443 · cited 1×
“This result is similar to the effect of allosteric agonists of the cannabinoid CB1 receptor, because their binding to the receptor results in a conformation change that increases the affinity of the orthosteric agonist to the receptor [46].”
BackgroundØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Underwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., & Reedtz-Runge, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033829 · Cited by 295 · cited 2×
“The V36A mutation in the GLP-1R has previously been shown to affect GLP-1 binding to the orthosteric binding site [35].”
BackgroundMa, L., Seager, M. A., Wittmann, M., Jacobson, M., Bickel, D., Burno, M., Jones, K., Graufelds, V. K., Xu, G., Pearson, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900903106 · Cited by 285 · cited 1×
“Additionally, the allosteric agonist AC-42 binds to the M1 muscarinic acetylcholine receptor, which results in ERK phosphorylation and intracellular Ca mobilisation but not internalisation of the receptor [41, 42].”
BackgroundSmall-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232 · cited 9×
“However, compounds 2 and B not only induce insulin secretion but also inhibit GLP-1R internalisation [17, 18, 20], indicating that GLP-1R may use multiple and compensatory pathways to induce insulin secretion in pancreatic islets.”
BackgroundResultInfluentialGroer, C. E., Tidgewell, K., Moyer, R. A., Harding, W. W., Rothman, R. B., Prisinzano, T. E., & Bohn, L. M. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.028258 · Cited by 224 · cited 1×
“The μ-opioid receptor agonist, herkinorin, induces ERK1/2 phosphorylation but not internalisation of the receptor [40].”
BackgroundKoole, C., Wootten, D., Simms, J., Valant, C., Sridhar, R., Woodman, O. L., Miller, L. J., Summers, R. J., Christopoulos, A., & Sexton, P. M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065664 · Cited by 223 · cited 1×
“Compounds B and 2 have previously been reported to induce a small or no increase in intracellular Ca accumulation [4, 25, 39], which effect, however, on GLP-1R internalisation is unknown.”
BackgroundHolz, G. G., Leech, C. A., Heller, R. S., Castonguay, M., & Habener, J. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.14147 · Cited by 220
G-Protein-Coupled Receptors: From Classical Modes of Modulation to Allosteric Mechanisms
Bridges, T. M., & Lindsley, C. W. (2008) · ACS Chemical Biology · doi:10.1021/cb800116f · Cited by 179
Vahl, T. P., Paty, B. W., Fuller, B. D., Prigeon, R. L., & D’Alessio, D. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021479 · Cited by 173 · cited 1×
“GLP-1 is cleaved in secretory vesicles to form the bioactive peptides, GLP-1 (7–36)-NH2 and GLP-1 (7–37), bind to the GLP-1R with similar affinity and show similar potency [7,8].”
BackgroundHigh Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor
Montrose-Rafizadeh, C., Yang, H., Rodgers, B. D., Beday, A., Pritchette, L. A., & Eng, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21201 · Cited by 171 · cited 2×
“This is because internalisation of the receptor can lead to dampening of its biological response [32].”
BackgroundKim Chung, L. T., Hosaka, T., Yoshida, M., Harada, N., Sakaue, H., Sakai, T., & Nakaya, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.015 · Cited by 158
Real-time trafficking and signaling of the glucagon-like peptide-1 receptor
Roed, S. N., Wismann, P., Underwood, C. R., Kulahin, N., Iversen, H., Cappelen, K. A., Schäffer, L., Lehtonen, J., Hecksher-Soerensen, J., Secher, A., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.11.010 · Cited by 153 · cited 2×
“Cells were imaged twice (0 and 3 min) before adding agonist and for every 3min after stimulating with agonist for 60min, as described previously [21, 29].”
BackgroundMethodKuna, R. S., Girada, S. B., Asalla, S., Vallentyne, J., Maddika, S., Patterson, J. T., Smiley, D. L., DiMarchi, R. D., & Mitra, P. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2012 · Cited by 150
Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143
Green, B. D., Irwin, N., Duffy, N. A., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.043 · Cited by 121 · cited 3×
“Both GLP-1R agonists, liraglutide (a DPP-IV resistant GLP-1) and exenatide (a synthetic version of exendin-4), are currently in use as drugs for the treatment of patients with type 2 diabetes [14–16].”
BackgroundSerre, V., Dolci, W., Schaerer, E., Scrocchi, L., Drucker, D., Efrat, S., & Thorens, B. (1998) · Endocrinology · doi:10.1210/endo.139.11.6295 · Cited by 110 · cited 1×
“Truncated version of GLP-1 (GLP-1 [9–36]-NH2/[9–37]) and exendin-4 (exendin-3, Ex[9–39]) also bind to the GLP-1R but function as antagonists [9, 10, 12, 13].”
BackgroundWootten, D. L., Savage, E. E., Willard, F. S., Bueno, A. B., Sloop, K. W., Christopoulos, A., & Sexton, P. M. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084525 · Cited by 91 · cited 4×
“However, the EC50 of GLP-1 for inducing cAMP production is 3 orders of magnitude lower than that of compounds 2 and B (Fig 1D) [25].”
BackgroundResultInfluentialExenatide (Byetta) as a Novel Treatment Option for Type 2 Diabetes Mellitus
Bond, A. (2006) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2006.11928181 · Cited by 87
A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification
Nolte, W. M., Fortin, J.-P., Stevens, B. D., Aspnes, G. E., Griffith, D. A., Hoth, L. R., Ruggeri, R. B., Mathiowetz, A. M., Limberakis, C., Hepworth, D., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1581 · Cited by 86 · cited 3×
“Taken together, these results demonstrate antagonists Ex(9–39) and JANT-4 competitively inhibit hGLP-1R activation by GLP-1 but not by compounds 2 or B, confirming they act through a binding site or binding sites distinct to the orthosteric binding site on the GLP-1R [34].”
BackgroundThompson, A., & Kanamarlapudi, V. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.015 · Cited by 82 · cited 10×
“Intracellular localisation of hGLP-1R expression was assessed by immunofluorescence as described previously [20, 28].”
BackgroundMethodInfluentialSelf-citationSmall Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor
Willard, F. S., Bueno, A. B., & Sloop, K. W. (2012) · Experimental Diabetes Research · doi:10.1155/2012/709893 · Cited by 81
Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor
Willard, F. S., & Sloop, K. W. (2012) · Experimental Diabetes Research · doi:10.1155/2012/470851 · Cited by 79 · cited 1×
“The agonist occupied GLP-1R signals through both the Gαs and Gαq coupled pathways [3, 5, 6].”
BackgroundAllosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery
Wootten, D. L., Savage, E. E., Valant, C., May, L. T., Sloop, K. W., FICORILLI, J. V., Showalter, A. D., Willard, F. S., Christopoulos, A., & Sexton, P. M. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079319 · Cited by 78 · cited 1×
“Furthermore, they have also been shown to allosterically modulate the function of GLP-1 [9–36]-NH2 (GLP-1 metabolite) by sensitising the GLP-1R for activation by this metabolite [18, 34, 44, 45].”
BackgroundMathi, S. K., Chan, Y., Li, X., & Wheeler, M. B. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.4.9913 · Cited by 71
TAKHAR, S., Gyomorey, S., Su, R., Mathi, S. K., Li, X., & Wheeler, M. B. (1996) · Endocrinology · doi:10.1210/en.137.5.2175 · Cited by 70 · cited 2×
“Additionally, the K334A mutation in the GLP-1R, which has previously been shown to prevent coupling of the receptor to the Gαs subunit [36, 37], reduced cAMP production stimulated by GLP-1, compound 2 and compound B.”
BackgroundCoopman, K., Huang, Y., Johnston, N., Bradley, S. J., WILKINSON, G. F., & Willars, G. B. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166009 · Cited by 64 · cited 4×
“These compounds binding site(s) on GLP-1R is spatially and functionally distinct from the primary agonist GLP1 (orthosteric) binding site [4, 19].”
BackgroundInfluentialLópez de Maturana, R., & Donnelly, D. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03492-0 · Cited by 60 · cited 1×
“Truncated version of GLP-1 (GLP-1 [9–36]-NH2/[9–37]) and exendin-4 (exendin-3, Ex[9–39]) also bind to the GLP-1R but function as antagonists [9, 10, 12, 13].”
BackgroundPatterson, J. T., Ottaway, N., Gelfanov, V. M., Smiley, D. L., Perez-Tilve, D., Pfluger, P. T., Tschöp, M. H., & DiMarchi, R. D. (2011) · ACS Chemical Biology · doi:10.1021/cb1002015 · Cited by 53
Zahn, K., Eckstein, N., Tränkle, C., Sadée, W., & Mohr, K. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.720 · Cited by 46 · cited 1×
“In contrast to compounds 2 and B, allosteric agonist alcuronium inhibits the actions of orthosteric agonist pilocarpine on the M2 muscarinic acetylcholine receptor [47].”
BackgroundIrwin, N., Flatt, P. R., Patterson, S., & Green, B. D. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.022 · Cited by 38 · cited 1×
“Compounds 2 and B have been described as ago-allosteric agonists [4, 17, 18, 33].”
BackgroundKanamarlapudi, V., Brandom, K. G., & Yun, H. (2007) · Journal of Cell Science · doi:10.1242/jcs.03373 · Cited by 37 · cited 1×
“Cells were imaged twice (0 and 3 min) before adding agonist and for every 3min after stimulating with agonist for 60min, as described previously [21, 29].”
MethodSelf-citationLi, N., Lu, J., & Willars, G. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047936 · Cited by 35 · cited 1×
“Furthermore, they have also been shown to allosterically modulate the function of GLP-1 [9–36]-NH2 (GLP-1 metabolite) by sensitising the GLP-1R for activation by this metabolite [18, 34, 44, 45].”
BackgroundType 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Aiysha Thompson, K. (2013) · Clinical & Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 33 · cited 5×
“Both GLP-1R agonists, liraglutide (a DPP-IV resistant GLP-1) and exenatide (a synthetic version of exendin-4), are currently in use as drugs for the treatment of patients with type 2 diabetes [14–16].”
BackgroundInfluentialThomas, R. L., Langmead, C. J., Wood, M. D., & Challiss, R. A. J. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160242 · Cited by 32 · cited 1×
“Additionally, the allosteric agonist AC-42 binds to the M1 muscarinic acetylcholine receptor, which results in ERK phosphorylation and intracellular Ca mobilisation but not internalisation of the receptor [41, 42].”
BackgroundCytohesin 2/ARF6 regulates preadipocyte migration through the activation of ERK1/2
Davies, J. C. B., Tamaddon-Jahromi, S., Jannoo, R., & Kanamarlapudi, V. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.09.023 · Cited by 28 · cited 1×
“3M dithiothreitol [DTT]) was incubated at room temperature for 1h and then used to detect hGLP-1R expression by immunoblotting using the anti-GFP and anti-VSVG antibodies [30, 31].”
MethodSelf-citationThompson, A., & Kanamarlapudi, V. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.012 · Cited by 25 · cited 1×
“In addition, the C-terminus of GLP-1R plays an important role in agonist-induced internalisation of the receptor [22, 23].”
BackgroundSelf-citationKanamarlapudi, V. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.534156 · Cited by 25 · cited 2×
“The V36A and K334A mutations within the hGLP-1R were generated using Quickchange II XL site-directed mutagenesis kit (Agilent Technologies, Leicestershire, UK) and SP-VSVG-hGLP-1RΔN23-GFP plasmid as the template [27].”
MethodSelf-citationThompson, A., & Kanamarlapudi, V. (2014) · Scientific Reports · doi:10.1038/srep07410 · Cited by 24 · cited 4×
“Intracellular localisation of hGLP-1R expression was assessed by immunofluorescence as described previously [20, 28].”
MethodInfluentialSelf-citationVázquez, P., Roncero, I., Blázquez, E., & Álvarez, E. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.06179 · Cited by 23 · cited 2×
“It has been shown that the intracellular C-terminal domain of GLP-1R is important for agonist-induced internalisation of the receptor [23].”
BackgroundADP-ribosylation factor 6 regulates endothelin-1-induced lipolysis in adipocytes
Davies, J. C. B., Bain, S. C., & Kanamarlapudi, V. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.012 · Cited by 22 · cited 1×
“3M dithiothreitol [DTT]) was incubated at room temperature for 1h and then used to detect hGLP-1R expression by immunoblotting using the anti-GFP and anti-VSVG antibodies [30, 31].”
MethodSelf-citationCheong, Y.-H., Kim, M.-K., Son, M.-H., & Kaang, B. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.004 · Cited by 17 · cited 1×
“The small molecule agonists, compounds 2 and B, have been shown to modulate differently the GLP-1R activation [24, 25].”
BackgroundLiraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives
Stephens, J., & Edavalath, M. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s6358 · Cited by 17
Self-citation
Cited by
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Self-citationTreatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
Conserved class B GPCR activation by a biased intracellular agonist
Zhao, L., He, Q., Yuan, Q., Gu, Y., He, X., Shan, H., Li, J., Wang, K., Li, Y., Hu, W., et al. (2023) · Nature · doi:10.1038/s41586-023-06467-w · Cited by 64
Treatment of type 2 diabetes: future approaches
Bailey, C. J., & Day, C. (2018) · British Medical Bulletin · doi:10.1093/brimed/ldy013 · Cited by 61
“This modifies the conformation and signalling activity of the GLP-1 receptors, offering the potential to increase receptor binding of endogenous GLP-1 or exogenous peptide GLP-1 receptor agonists.(26) Whether the profile of metabolic and other effects generated in this way will exactly replicate native GLP-1 remains t…”
Background
Metadata
- Authors
- Thompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V.
- Affiliations
- Swansea University (GB)
- Corresponding author
- Kanamarlapudi, Venkateswarlu
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-04-21
- Volume
- 11
- Issue
- 4
- Pages
- e0154229
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4839733
- OpenAlex
- W2341529564
- Cited by
- 19
- References
- 48
- Citations by year
- 2024: 3 · 2023: 3 · 2021: 6 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 1
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Biotechnology and Biological Sciences Research Council (BB/F017596/1, BB/C515455/2)
- Medical Research Council (G0401232)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, GLP-1 receptor agonists, receptor internalization, G protein-coupled receptor signaling, cAMP production, intracellular calcium accumulation, ERK1/2 phosphorylation, orthosteric binding site, receptor conformational change, small molecule agonists
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Cyclic AMP, Binding Sites, Calcium, Endocytosis, Humans, Mutation, Peptide Fragments, Peptides, Phosphorylation, Venoms, Immunoblotting, Signal Transduction, Microscopy, Confocal, Intracellular Space, Extracellular Signal-Regulated MAP Kinases, Glucagon-Like Peptide 1, Small Molecule Libraries, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.